Communiqués BioNTech SE

Actions

BNTX

US09075V1026

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 21/07/2026			Varia. 5j.	Varia. 1 janv.
92,33 ^USD	+0,18%		+2,13%	-3,01%

16/07	Arbutus Biopharma et Genevant poursuivent Pfizer et BioNTech pour violation de brevets sur les nanoparticules lipidiques	MT
14/07	Où l'intelligence artificielle mènera-t-elle l'industrie pharmaceutique à long terme ?

Communiqués

21/07	BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026	GL
24/06	A Sovereign Bet On Science Could Save Millions of Lives	AQ
30/05	Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial	GL
22/05	BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting	GL
18/05	BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026	AQ
15/05	BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026	GL
07/05	BioNTech Announces New ADS Repurchase Program	GL
05/05	BioNTech : BNTX 1Q 2026 Presentation	PU
05/05	BioNTech : Q1 2026 Präsentation	PU
05/05	BioNTech : BNTX Q1 2026 Exhibit 99.1 (Quarterly Report)	PU
05/05	BioNTech : Q1 2026 Finanzbericht	PU
05/05	BioNTech : BNTX 4QFY 2025 Presentation FINAL 200326 v2	PU
05/05	BioNTech Announces First Quarter 2026 Financial Results and Corporate Update	GL
21/04	BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026	GL
13/04	BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer	AQ
11/04	BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer	GL
26/03	EU General Court: Technical Vaccine Data Does Not Have To Be Disclosed On Request	AQ
24/03	BioNTech : Nachhaltigkeitsbericht 2025 (716624)	PU
24/03	BioNTech : Nachhaltigkeitsbericht 2025	PU
24/03	BioNTech : Nachhaltigkeitsbericht 2025 (db0718)	PU
24/03	BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer	GL
20/03	BioNTech : BNTX 4QFY 2025 Presentation FINAL 200326	PU
17/03	The Nomination Committee of Flerie AB proposes the election of an additional Board member	AQ
10/03	BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses	AQ
10/03	BioNTech : BNTX 4QFY 2025 Presentation v1	PU